ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The drug services firm Bachem Group has won two contracts for large-scale peptide production that it expects to be worth $26 million in 2023 and $156 million in 2024. Manufacturing will take place primarily at a peptide and oligonucleotide facility that Bachem is building in Bubendorf, Switzerland, at a cost of $228 million. An additional $156 million will go to a second expansion. Projects are also underway at Bachem sites in Switzerland, the UK, and the US.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter